Related Experiment Video
Updated: Nov 27, 2025

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
How Should Risk Managers Respond to Cases for Which No Risk Profile Exists?
Douglas E Paull1, Paul N Uhlig2
1Assistant professor at the Georgetown University School of Medicine in Washington, DC.
Abstract:
Rapid innovation makes some devices available for patient implantation prior to extensive preclinical trials. This article reviews information that risk managers can utilize to help patient-subjects and clinician-researchers make informed decisions about new device implantation in the absence of preclinical trial data. Novel devices should be regarded by risk managers as sources of unknowns with potential for procedural complications and other harms. Risk-benefit analyses during informed consent should include patient-subjects' preferences, experience of the implanting surgical team, disclosure of conflicts of interest, and postprocedure follow-up planning. Checklists can help risk managers facilitate critical conversations and decision making about whether to implant devices with no extant risk profile.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Response Surface Methodology
The process of RSM involves several key steps:
Psychological Responses to Stress
Hazard Rate
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Relative Risk

